Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study

INTRODUCTION: Safe and effective pharmacological treatment is of paramount importance for treating severe psoriasis. Brodalumab, a monoclonal antibody against interleukin (IL) 17 receptor A, was granted marketing authorisation in the EU in 2017. The European Medicines Agency requested a postauthoris...

Descripción completa

Detalles Bibliográficos
Autores principales: Reilev, Mette, Jensen, Peter Bjødstrup, Ranch, Lise Skov, Egeberg, Alexander, Furu, Kari, Gembert, Karin, Hagg, David, Haug, Ulrike, Karlstad, Øystein, Reutfors, Johan, Schäfer, Wiebke, Schwartz, Sarina, Smits, Elisabeth, Holthius, Emily, Herings, Ron, Trifirò, Gianluca, Kirchmayer, Ursula, Rosa, Alessandro Cesare, Belleudi, Valeria, Gini, Rosa, Støvring, Henrik, Hallas, Jesper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896233/
https://www.ncbi.nlm.nih.gov/pubmed/36725094
http://dx.doi.org/10.1136/bmjopen-2022-066057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896233/
https://www.ncbi.nlm.nih.gov/pubmed/36725094
http://dx.doi.org/10.1136/bmjopen-2022-066057

Ejemplares similares